GE HealthCare Technologies Inc.
GEHC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GEHC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GEHC
GE HealthCare Technologies Inc. is a global medical technology and pharmaceutical diagnostics company operating through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).
Key risk: Geopolitical instability impact
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 13 clinical trials · 1 catalyst for GE HealthCare Technologies Inc..
GE HealthCare Technologies Inc. is a global medical technology and pharmaceutical diagnostics company operating through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).
- Cash and equivalents of $2,288.0M as of 2026-03-31 [sec].
- Total revenue of $5,131.0M and net income of $389.0M for the quarter ended 2026-03-31 [sec].
- Total debt of $10,136.0M and shareholders' equity of $10,379.0M as of 2026-03-31 [sec].
- For the three months ended June 30, 2026, total revenues were $5,295 million, growing 5.7% as reported and 3.5% organically [sec_mda · as of 2026-07-29].
- Cash, cash equivalents, and restricted cash balance was $2,105 million as of June 30, 2026 [sec_mda · as of 2026-07-29].
What works
- Strong organic revenue growth in Advanced Visualization Solutions (AVS) and Pharmaceutical Diagnostics (PDx) segments, with AVS growing 5.0% organically in Q2 2026 [sec_mda · as of 2026-07-29].
- Historically positive cash flows from operating activities, with free cash flow of $112 million in Q1 2026 [sec_mda · as of 2026-04-29].
- Access to $3,500 million in revolving credit facilities and a $750 million delayed draw term loan facility, providing liquidity flexibility [sec_mda · as of 2026-02-04].
What to weigh
- Geopolitical instability, including the conflict in the Middle East, adversely impacted costs, supply chains, and logistics in Q2 2026 [sec_mda · as of 2026-07-29].
- Tariffs and trade restrictions could materially impact financial results, and mitigation actions are not expected to fully offset additional costs [sec_mda · as of 2026-02-04].
- Sustained cost inflation or constrained availability of critical components (e.g., memory chips, logistics) could negatively impact production and delivery [sec_mda · as of 2026-07-29].
From the filings
Quoted directly from source documents.
Total revenues for Q2 2026 were $5,295 million, with 5.7% reported growth and 3.5% organic growth.
“For the three months ended June 30, 2026 Total revenues were $5,295 million, growing 5.7% as reported and 3.5% organically*.”
SEC MD&A · July 29, 2026
Cash, cash equivalents, and restricted cash was $2,105 million as of June 30, 2026.
“As of June 30, 2026, our Cash, cash equivalents, and restricted cash balance in the Condensed Consolidated Statements of Financial Position was $2,105 million.”
SEC MD&A · July 29, 2026
Geopolitical instability in the Middle East adversely impacted costs, supply chains, and logistics in Q2 2026.
“Global geopolitical instability, including the conflict in the Middle East, adversely impacted our costs, supply chains, and logistics during the second quarter of 2026.”
SEC MD&A · July 29, 2026
Tariffs and trade restrictions could materially impact financial results, and mitigation actions are not expected to fully offset additional costs.
“Additional tariffs or other trade restrictions by the U.S. or other countries where we do significant business, or other restrictions on specific industries, such as pharmaceuticals, could further materially impact our results in the future. While we are taking actions to mitigate the impact of tariffs, we do not expect that our mitigation actions will fully offset the additional costs or other negative impacts resulting from the tariffs.”
SEC MD&A · February 4, 2026
Catalyst timeline
- 2028-09-16 · Patent/Exclusivity Expiry: VIZAMYL — VIZAMYL, a pharmaceutical diagnostic product, faces patent or exclusivity expiry, which could impact future revenue from that product.
Risks & what to watch (4)›
Key risks
- Geopolitical instability impact — Middle East conflict adversely impacted costs, supply chains, and logistics in Q2 2026 [sec_mda · as of 2026-07-29].
- Tariff and trade restriction risk — Additional tariffs could materially impact results; mitigation actions may not fully offset costs [sec_mda · as of 2026-02-04].
- Supply chain and cost inflation — Sustained cost inflation or constrained availability of critical components could impact production and delivery [sec_mda · as of 2026-07-29].
- High debt levels — Total debt of $10,136.0M as of 2026-03-31, with shareholders' equity of $10,379.0M [sec].
What to watch
- Impact of geopolitical instability and supply chain disruptions on future costs and revenues [sec_mda · as of 2026-07-29].
- Effectiveness of tariff mitigation actions and potential additional trade restrictions [sec_mda · as of 2026-02-04].
- Organic revenue growth trends in AVS and PDx segments, which drove recent performance [sec_mda · as of 2026-07-29].
- Cash flow generation and debt servicing ability given total debt of $10,136.0M [sec].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run GE HealthCare Technologies Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GE HealthCare Technologies Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 2.46 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~748d
8 buys · 0 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,257
Total value held
$27.49B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 57,728,376 | $4.11B |
| blackrock, inc. | 35,984,327 | $2.56B |
| dodge & cox | 31,312,064 | $2.23B |
| state street corp | 20,538,476 | $1.46B |
| vanguard portfolio management llc | 19,183,157 | $1.37B |
| harris associates l p | 15,594,988 | $1.11B |
| geode capital management, llc | 12,399,635 | $879.3M |
| barrow hanley mewhinney & strauss llc | 11,884,588 | $845.9M |
| hotchkis & wiley capital management llc | 9,967,873 | $709.5M |
| jpmorgan chase & co | 8,964,669 | $616.5M |
Showing top 10 of 1,257 institutional holders of GE HealthCare Technologies Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 3.0%
- Days to cover
- 2.7
- Shares short
- 12,059,066
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GEHC short interestGovernance
Frequently asked questions
What is the AI investment thesis for GE HealthCare Technologies Inc.?
GE HealthCare Technologies Inc. is a global medical technology and pharmaceutical diagnostics company operating through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).
What is GE HealthCare Technologies Inc.'s next catalyst?
GE HealthCare Technologies Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VIZAMYL" — expected September 16, 2028.
Who is the CEO of GE HealthCare Technologies Inc.?
Mr. Peter J. Arduini is the chief executive officer of GE HealthCare Technologies Inc. (GEHC).
Where is GE HealthCare Technologies Inc. headquartered?
GE HealthCare Technologies Inc. (GEHC) is headquartered in Chicago, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.